FDA Grants Priority Review to Palvella Therapeutics’ Qtorin
Palvella Therapeutics said the FDA granted priority review to Qtorin, which the company says could become the first FDA-approved therapy for microcystic lymphatic malformations.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.